Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma - PubMed
3 hours ago
- #bispecific antibodies
- #cilta-cel
- #multiple myeloma
- Real-world outcomes comparison between cilta-cel and BCMA-targeting bispecific antibodies for relapsed/refractory multiple myeloma.
- Publication reference includes PMID 42169674 and DOI 10.1080/10428194.2026.2673104.
- Article mentions availability of full text sources and research materials.